Sci Transl Med:研究者发现潜在的艾滋病治疗新靶点

2012-06-05 T.Shen 生物谷

近日,美国加州大学旧金山分校(UCSF)的研究者通过研究发现,在实验室感染猿猴免疫缺陷病毒(SIV)的猕猴,因其机体肠道内有某种特定类型的免疫细胞,相比其它猴类血液中的病毒量水平较低,而且感染6个月后,猕猴可以自如地控制SIV。SIV是一种可以感染灵长类动物的反转录病毒,人类感染SIV后可以慢慢发展为HIV感染。在猕猴中SIV可以促使猴艾滋病,因此在动物中研究SIV可以为理解HIV如何在人体内发挥

近日,美国加州大学旧金山分校(UCSF)的研究者通过研究发现,在实验室感染猿猴免疫缺陷病毒(SIV)的猕猴,因其机体肠道内有某种特定类型的免疫细胞,相比其它猴类血液中的病毒量水平较低,而且感染6个月后,猕猴可以自如地控制SIV。SIV是一种可以感染灵长类动物的反转录病毒,人类感染SIV后可以慢慢发展为HIV感染。在猕猴中SIV可以促使猴艾滋病,因此在动物中研究SIV可以为理解HIV如何在人体内发挥作用提供新的思路。UCSF的研究者的研究更清楚地阐明了为什么有些HIV感染者可以更轻松自如的控制HIV而不受其危害,而且可以生活地更好。

机体内的Th17细胞具有保护机体的效应,它们是一组在灵长类和人类肠道中发现的具有抵御疾病的免疫细胞,可以有效杀灭HIV,UCSF研究者之前的研究发现了SIV的感染可以引起机体保护性免疫效应的出错,进而导致肠道内Th17细胞的保护效应降低,最终对细菌、病毒的粘膜防御力降低。更有意思的是,在研究中,Th17细胞并不会被SIV所侵袭,比如非洲绿猴感染SIV后并不会表现出病症。

携带有更多Th17细胞的动物可以很好的控制SIV,并且这部分取决于猕猴可以通过产生更多的SIV特异性CD4活性T细胞从而产生更为有效的免疫效应来抵御感染。研究者下一步的研究是观察Th17细胞的更多效力,研究者可能会检测Th17细胞的白细胞介素17和细胞因子的释放量,并且检测其是否具有某种效应。研究者表示,如果在治疗过程中可以增加Th17细胞的数量,这将会增加病人机体对于HIV的抵御能力。相关研究成果于5月30日刊登在了国际著名杂志Science Translational Medicine上。

这项研究中,研究者测定了16只猕猴肠道中的Th17细胞的水平,然后用SIV感染这些猕猴,研究者发现肠道内有更多Th17细胞的猕猴可以更好的静置SIV病毒。随后研究者给高水平Th17细胞的猕猴喂食药物,药物可以去除Th17细胞,最后研究者发现,降低Th17水平的猕猴相比之前控制SIV病毒的能力明显降低。

早期的研究只是阐明了病毒感染的起因和炎性结果,研究者发现炎症可以诱导一种酶,这种酶可以破坏Th17的功能,失去Th17的保护效应,因此疾病会迅速蔓延。相反,研究者现在发现了含有较多Th17细胞的动物可以降低病毒感染的风险,后期研究者们将进行深入研究,看看是否可以为临床上提供一些治疗思路和建议。这项研究由美国国立卫生研究院等机构支持。

编译自http://www.sciencedaily.com/releases/2012/05/120530152207.htm

doi:10.1038/nature11095
PMC:
PMID:

Inhibitory receptors bind ANGPTLs and support blood stem cells and leukaemia development

Dennis J. Hartigan-O’Connor1,*,†, Kristina Abel2,3,‡, Koen K. A. Van Rompay3, Bittoo Kanwar1,4 and Joseph M. McCune1

 

The mechanisms by which some HIV-infected subjects resist disease progression, whereas others progress rapidly, are incompletely understood. Viral and host genetic factors, such as nef deletions and major histocompatibility complex alleles, explain a portion of the observed variability. However, it has been difficult to identify host immune functions that may be present before infection and that allow resistance to lentiviral disease progression. Here, we show that simian immunodeficiency virus replication in the infected rhesus macaque is limited by the size of the preexisting T helper 17 (TH17) cell compartment: Animals with a high representation of such cells in blood and intestinal tissue before infection experienced peak and set-point viral loads about one log unit lower than those with a lower representation of TH17 cells. Reciprocally, treatment of macaques with interleukin-2 and granulocyte colony-stimulating factor before infection led to depletion of TH17 cells, reduction of the ratio between TH17 cells and CD3+CD4+CD25+CD127low regulatory T cells, and higher viral loads for 6 months after infection. These results demonstrate that the composition of the host immune system before infection has an influence on the course of disease after infection. Furthermore, to the extent that this influence shapes and interacts with T cell–mediated responses to virus, our findings provide a new framework for understanding interindividual variation in responses to therapies and vaccines against HIV.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1656520, encodeId=bcb716565201f, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun May 05 03:50:00 CST 2013, time=2013-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032697, encodeId=31cc203269ef5, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Jul 19 13:50:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067086, encodeId=5088206e08612, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Nov 04 06:50:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288112, encodeId=1db212881125a, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517335, encodeId=d3e8151e335c4, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605739, encodeId=655d1605e39ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
    2013-05-05 bsmagic9140
  2. [GetPortalCommentsPageByObjectIdResponse(id=1656520, encodeId=bcb716565201f, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun May 05 03:50:00 CST 2013, time=2013-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032697, encodeId=31cc203269ef5, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Jul 19 13:50:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067086, encodeId=5088206e08612, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Nov 04 06:50:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288112, encodeId=1db212881125a, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517335, encodeId=d3e8151e335c4, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605739, encodeId=655d1605e39ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
    2012-07-19 stfoxst
  3. [GetPortalCommentsPageByObjectIdResponse(id=1656520, encodeId=bcb716565201f, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun May 05 03:50:00 CST 2013, time=2013-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032697, encodeId=31cc203269ef5, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Jul 19 13:50:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067086, encodeId=5088206e08612, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Nov 04 06:50:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288112, encodeId=1db212881125a, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517335, encodeId=d3e8151e335c4, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605739, encodeId=655d1605e39ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1656520, encodeId=bcb716565201f, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun May 05 03:50:00 CST 2013, time=2013-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032697, encodeId=31cc203269ef5, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Jul 19 13:50:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067086, encodeId=5088206e08612, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Nov 04 06:50:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288112, encodeId=1db212881125a, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517335, encodeId=d3e8151e335c4, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605739, encodeId=655d1605e39ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
    2012-06-07 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1656520, encodeId=bcb716565201f, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun May 05 03:50:00 CST 2013, time=2013-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032697, encodeId=31cc203269ef5, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Jul 19 13:50:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067086, encodeId=5088206e08612, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Nov 04 06:50:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288112, encodeId=1db212881125a, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517335, encodeId=d3e8151e335c4, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605739, encodeId=655d1605e39ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1656520, encodeId=bcb716565201f, content=<a href='/topic/show?id=3ca31e71903' target=_blank style='color:#2F92EE;'>#TRA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17719, encryptionId=3ca31e71903, topicName=TRA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=757b24868428, createdName=bsmagic9140, createdTime=Sun May 05 03:50:00 CST 2013, time=2013-05-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032697, encodeId=31cc203269ef5, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Thu Jul 19 13:50:00 CST 2012, time=2012-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2067086, encodeId=5088206e08612, content=<a href='/topic/show?id=d0841e75535' target=_blank style='color:#2F92EE;'>#Transl#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17755, encryptionId=d0841e75535, topicName=Transl)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Sun Nov 04 06:50:00 CST 2012, time=2012-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1288112, encodeId=1db212881125a, content=<a href='/topic/show?id=f10658e342d' target=_blank style='color:#2F92EE;'>#新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58734, encryptionId=f10658e342d, topicName=新靶点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517335, encodeId=d3e8151e335c4, content=<a href='/topic/show?id=817b64646b3' target=_blank style='color:#2F92EE;'>#治疗新靶点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64646, encryptionId=817b64646b3, topicName=治疗新靶点)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=251911073486, createdName=12498f1em11(暂无昵称), createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1605739, encodeId=655d1605e39ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Jun 07 09:50:00 CST 2012, time=2012-06-07, status=1, ipAttribution=)]

相关资讯

2011年SCI收录植物科学学科期刊199种目录

2011年SCI收录植物科学学科期刊199种, 其中SCI收录102种、SCI E收录199种。 2010年JCR 收录植物科学学科期刊188种,其中影响因子28以上有1种、影响因子10以上有2种、影响因子9以上有2种、影响因子6以上有3种、影响因子5以上有2种、影响因子4以上有8种、影响因子3以上有9种、影响因子2以上有29种,2010年植物科学期刊影响因子前10名期刊如下: 1、 

预告:MedSci 2012“临床科研中国行”全国巡回讲座——南京站

MedSci作为专业科研与临床学术服务平台,致力于临床科研教育培训与医学学术服务指导,以全面提升中国医学科研学术水平,全面对接中国与国际最新研究成果。 MedSci自2009年开始,推出“临床科研中国行”公益活动,围绕“SCI论文写作与发表,医学统计与数据挖掘,循证医学与荟萃分析,国家自然科学基金申请辅导”四大主题,展开全国公益巡回授课;历经三年,讲座场次已近三百场,足迹遍布上海、天津、北京、成

“十二五”国家对SCI论文提出了更高的要求

    近日,《国家“十二五”科学和技术发展规划》在科技部网站全文发布了。该发展规划是按照国务院的部署要求,有科技部牵头,会同发改委、财政部、教育部、中科院、工程院、基金委、中国科协、国家国防科技局等有关重量级单位一起研究制定的。     顺着网址链接点击进去大概浏览了一下,该规划制定了“十二五”期间科技发展的总体目标,其中印象最深的是以

小心陷入文章数量的陷阱

孙学军第二军医大学 主任医师/教授 对于一般科研人员追求发表论文,追求影响因子和论文数量,这本无可厚非。但如果这种追求数量的现象太明显太过分,也会带来很多副作用,甚至导致发表越多越有害的尴尬局面。一般情况下,这种不利局面不是那么容易出现,但一旦作者在某个领域逐渐有了一些影响,这种不利效应就很容易体现。这里列举一些单纯追求发表论文数量的现象。 一、克隆论文采用完全类似的研究思路,换用不同的动物模

我在SCI文章审稿中所遭遇的那些事

最近有很多朋友都问我同样一个问题:如何得到第一次审稿机会?我一时也答不上来,后来静下来想了想,还是写点什么吧。去年11月到现在,我初步统计了一下,在不到一年的时间里,经我审理和修改编辑的稿件过百篇,也就是说在我过去的一年里平均每3天审一篇稿。其中不乏有影响因子超过10的国际权威期刊,也有刚被SCI收录的或正在向SCI冲刺的那类杂志。涉及面就更广了,包括生物学,农学,医学,矿物学和营养学等不同领域,

Cell Mol Life Sci:科学家发现新的炎症治疗目标

称为初级纤毛的微小细胞器是抗击炎症的关键,伦敦玛丽大学的科学家们发现了一种新的抗击炎症的治疗目标。 相关研究论文发表在Cellular and Molecular Life Sciences杂志上,研究人员发现称为初级纤毛的微小细胞器对调节炎症反应很重要。这一发现可能为百万计患有关节炎的人带来潜在的新的治疗方法。 Martin Knight博士说:“虽然初级纤毛已经发现了有一个多世纪前,但我们